PARP1 and atherosclerosis: Different works have reported that both the pharmacological inhibition of PARP and a deficiency of PARP-1 have a protective role in inflammatory diseases, such as LPS-induced septic shock, uveitis, colitis, streptozotocin-induced diabetes, asthma-related lung inflammation, and atherosclerosis [33, 51–55].